EP0497952A1 - Composition destinee au traitement topique du psoriasis - Google Patents

Composition destinee au traitement topique du psoriasis

Info

Publication number
EP0497952A1
EP0497952A1 EP91915231A EP91915231A EP0497952A1 EP 0497952 A1 EP0497952 A1 EP 0497952A1 EP 91915231 A EP91915231 A EP 91915231A EP 91915231 A EP91915231 A EP 91915231A EP 0497952 A1 EP0497952 A1 EP 0497952A1
Authority
EP
European Patent Office
Prior art keywords
corn
composition
weight
acid
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP91915231A
Other languages
German (de)
English (en)
Inventor
Tibor Keri
Sándor JANCSO
Ilona Kristof
Veronika Pal
Erzsébet SZABO
Livia Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Works PLC
Original Assignee
Biogal Gyogyszergyar Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogal Gyogyszergyar Rt filed Critical Biogal Gyogyszergyar Rt
Publication of EP0497952A1 publication Critical patent/EP0497952A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • composition for the topical treatment of psoriasis Composition for the topical treatment of psoriasis
  • the invention relates to compositions suitable for the topical treatment of psoriasis as well as to the process for the preparation of said compositions.
  • compositions according to the invention contain the extract of different parts of maize plant (Zea mays) together with gamma-linolic acid as active ingredient.
  • the incidence of the psoriasis is different but it occurs all over the world, men and women can equally suffer from it and the number of the patients amounts to 0.3-4.8% of the entire population.
  • the illness can occur at any age, but most frequently people of the age from 10 to 30 years get ill.
  • the psoriasis belongs to the group of papulosquamous diseases which can be characterized by silverous squamae, considerable desquamation and anarchic cell division (karyokinesis) .
  • papulosquamous diseases which can be characterized by silverous squamae, considerable desquamation and anarchic cell division (karyokinesis) .
  • papules having a diameter of 3-5 mm and covered with parakeratosis appear which can gradually join and/or increase and so can form plaques having a diameter of several cm.
  • the local disorder of the relevant biochemical regulation belongs to the complex patogenetic factors as well.
  • the injury of the cAMP system can cause disorder in the epidermic autoregulation, so e.g. upon administration of lithium (which decreases the cAMP level) the psoriasis declines, however the inhibitors of enzymes (e.g. phosphordiesterase-PDE) decomposing the cAMP system, (e.g. Theophillin) influence advantageously the disease.
  • enzymes e.g. phosphordiesterase-PDE
  • the immune system, the arachidonic acid system as well as the polyamine metabolism and the various proteinases may also have a significant function in the formation of the disease as these systems differently influence the metabolism of the cyclic nucleotides.
  • Psoriasis guttata disseminated phenomena having a diameter of 0.5-1.5 cm are present on the whole skin.
  • Palmar-plantar psoriasis a less inflamed scaly, thickened alteration which can be rent at the edges and sterile blisters may occur.
  • Scalp psoriasis moderately inflamed, strongly scaly, generally itching, circumscribed phenomena, possibly covering the whole scalp, without any loss of hair.
  • Erythroderma psoriasis inflammatory and scaly symptoms appear on the whole skin, the plaques and papules are totally joined.
  • Psoriasis pustulosa is generally localized to the palm and planta, sometimes spreads on the whole skin surface. It is very severe, fatal disease.
  • Psoriasis arthropathy besides the charac ⁇ teristic symptoms of the skin, arthritis develops too, mainly (and initially) on one of the hands. According to our present knowledge all types of psoriasis are treated symptomatically. The local treatment has different aims: a) supression of the inflammatory reactions; b) removal of the accumulated squamae; c) decrease of the ephithelial cell activity; and d) prevention of the superinfection of the injured skin surface.
  • Coal-tar and tar of vegetable origin have been best known and widely used active ingredient which were applied in a concentration of 3-10% in form of ointments, painting and bath compositions.
  • active ingredient which were applied in a concentration of 3-10% in form of ointments, painting and bath compositions.
  • the use of these materials is avoided due to their carcinogenic side effects.
  • the phototherapy has also been known for a long time as it has been observed that the sunshine is very useful in the treatment of most types of psoriasis.
  • This therapy can be used alone or in combination with photosensitizing drugs.
  • the different bathes represent a very important additional treatment for all types of psoriasis diseases.
  • the removal of the squamae partly a decrease of the inflammatory symptoms can be achieved.
  • crysarobin of plant origin was also used for the treatment of psoriasis but due to its definite irritating side effect and pigmenting properties it is no longer applied.
  • Dermovate 21-chloro-9-fluoro-llbetal7-dihydroxy- 16beta-methylpregna-l,4-diene-3,20-dion
  • Diproderm 9- fluoro-llbeta,17,21-trihydroxy-l6beta-methylpregna-l,4- diene-3,20-dion-17,21-dipropionate
  • Diploren which can be used for the treatment of all types of psoriasis.
  • These drugs can only be applied very carefully as they have serious side effects (e.g. increase of the serum lipid level, hypertension, teratogenesis) .
  • the object of our invention was to ensure a topical composition for the treatment of psoriasis.
  • composition without any harmful side effect (e.g. carcinogenic, teratogenic, bone marrow damaging, adrenal disfunction producing effect, etc.) during the use of which no pigmentation, dehydratation, atrophy, super- infection on the injured skin surface occur and its application is not limited by interaction with other drugs.
  • harmful side effect e.g. carcinogenic, teratogenic, bone marrow damaging, adrenal disfunction producing effect, etc.
  • composition comprising the aqueous and/or pharmacologically accept ⁇ able organic solvent, preferably ethanolic extract of the young crop and/or beard (silk) and/or nodulous stalk and/or cob of maize plant and gamma-linolic acid can be used for the treatment of psoriasis without any side effect.
  • a composition comprising the aqueous and/or pharmacologically accept ⁇ able organic solvent, preferably ethanolic extract of the young crop and/or beard (silk) and/or nodulous stalk and/or cob of maize plant and gamma-linolic acid can be used for the treatment of psoriasis without any side effect.
  • HUP No. 195,915 USP No. 4,950,481
  • HUP No. 195,915 USP No. 4,950,481
  • the aqueous and/or ethanolic extract of the young crop and/or bread and/or nodulous stalk and/or cob of maize possesses skin sedative and skin regenerative effect.
  • the aqueous and/or ethanolic extract comprises the following active ingredients:
  • - carbohydrates mono- and oligosacharides, poly- sacharides
  • - fats oils
  • fatty acids phospholipides, glycolipides, galactolipides
  • phenolic materials flavonoides, coumarines, phenyltropanes and the phenolic materials
  • - terpenes sesquiterpenes, triterpenes, tetra- terpenes
  • the phospholipids are emulsifiers and are frequently used in cosmetic compositions as additives.
  • the gamma-linolic acid is an essential amino acid and being "body-friend 1 * (histotropic) , has no harmful side effect.
  • the Oenothera oil containing gamma-linolic acid has been successfully used mainly for the treatment of different complicated and uncomplicated cardiovascular diseases. It was able to decrease the thrombocyte aggregation, to normalize the lipid levels, however in the popular therapy it has been also used as oral antispasmodic and antiphlogistic agent.
  • the corn extract used so far in cosmetic compositions and having mild antiphlogistic effect together with gamma-linolic acid is efficient in the treatment of uncomplicated psoriasis diseases and after the treatment the patients became symptomless.
  • the composition contains only natural active ingredients it has no side effect.
  • the active ingredients of the composition according to the invention separately are not able to ensure the desired effect, they are effective against psoriasis only in case of their common use.
  • compositions suitable for the topical treatment of psoriasis which comprises an aqueous and/or pharma- ceutically acceptable organic solvent, preferably ethanolic extract of young corn-crops and/or corn-beard and/or nodulous corn-stalk and/or corn-cob together with gamma-linolic acid as active ingredient admixed with one or more solid and/or liquid carrier(s) and/or additives.
  • Concentration of the active ingredient is preferably 15-75% by weight.
  • a further object of the invention is a process for the preparation of a pharmaceutical composition suitable for the topical treatment of psoriasis in which the aqueous and/or pharmaceutically acceptable organic solvent, preferably ethanolic extract of young corn-crop and/or corn-beard and/or nodulous corn-stalk and /or corn-cob and gamma-linolic acid as active ingredient are admixed with one or more solid and/or liquid carrier(s) and/or additive(s) and the mixture thus obtained is formed into cream, emulsion or solution suitable for topical use.
  • the aqueous and/or pharmaceutically acceptable organic solvent preferably ethanolic extract of young corn-crop and/or corn-beard and/or nodulous corn-stalk and /or corn-cob and gamma-linolic acid as active ingredient are admixed with one or more solid and/or liquid carrier(s) and/or additive(s) and the mixture thus obtained is formed into cream, emul
  • corn extract used in the composition according • to the invention can be prepared in a manner known per se, e.g. the method described in US P No. 4,590,481 can be used.
  • the extract can be prepared e.g. by extracting the optionally dried plant pieces with a 2-30-fold amount - calculated for the dry mass of the plant - of water or aqueous solution of a cos etically acceptable organic solvent at a temperature between 15 and 95°C and separating the solid phase (plant pieces) from the liquid phase.
  • the extract can also be obtained as follows: plant pieces are crushed and steeped in the above mentioned solvents. The time of steeping can vary within a wide range, preferably between 5 and 48 hours.
  • the extraction is preferred as it can be carried out within a shorter time, (e.g. 30-60 minutes) .
  • the product obtained may be sterilized by heating it one or more times, preferably three-times to 80°C and heating it at this temperature for a short period.
  • water or the aqueous solution of a water-miscible pharmaceutically acceptable organic solvent e.g. ethanol is used.
  • compositions according to the invention contain the active ingredient and one or more pharmaceutically acceptable solid and/or liquid carrier(s) and/or additives.
  • compositions according to the invention may contain as solid carrier for example talc, zinc-oxide, bentonite, kaolin, colloidal silica, titanium-dioxide, corn-starch, potato starch.
  • Solid emulsifying agents e.g. fats, fatty alcohols, fatty acid, fatty acid esters, waxes can also be used as solid carriers.
  • the compositions according to the invention may contain as liquid carriers one or more pharmaceutically acceptable, to the skin non-irritative liquid solvent(s), e.g. water, ethanol or animal or vegetable oil.
  • compositions according to the invention may contain as carrier and emulsifier respectively in the cosmetic industry generally used fats, oils, waxes, fatty acids and esters and glycerides thereof obtained with higher alcohols.
  • the fatty acids may be straight or branched having 12-18 carbon atoms, may be saturated or unsaturated and may also be substituted with one or more hydroxy group(s) .
  • Suitable fatty acids are selected from the group consisting of undecenoic acid, laurylic acid, caprylic acid, myristic acid, palmitic acid, isopalmitic acid, stearic acid, isostearic acid, hydroxy-stearic acid, oleic acid, hydroxy-oleic acid, behenic acid, lanolinic acid, arachidonic acid, octyldecanoic acid, pentadecanoic acid or the mixture thereof.
  • Suitable fatty acid-esters are selected from the group consisting of isopropyl myristate, butyl yristate, octyldodecyl myristate, isocetyl myristate, cetyl myristate, ethyl palmitate, isopropyl palmitate, hexadecyl stearate, isopropyl isostearate, isostearyl isostearate, diisopropyl sebacate, cetyl ricinoleate, propylenglycol dipelargonate, 2-ethylhexyl isononate, hexyl laurate, 2-ethylhexyl stearate, fatty alcohol lactate having 12-16 carbon atoms, triglycerides of octanoic and dekanoic acids salicylate and the mixture thereof.
  • fatty alcohol e.g. alkohols having 14-22 carbon atoms
  • fatty alcohol e.g. alkohols having 14-22 carbon atoms
  • behenyl alcohol myristyl alcohol, arachidyl alcohol, stearyl alcohol, isostearil alcohol, cetyl alcohol, cetyl-stearyl alcohol, isocetyl alcohol, oleyl alcohol, lauryl alcohol
  • myristyl alcohol e.g. behenyl alcohol, myristyl alcohol, arachidyl alcohol, stearyl alcohol, isostearil alcohol, cetyl alcohol, cetyl-stearyl alcohol, isocetyl alcohol, oleyl alcohol, lauryl alcohol
  • oils or oil mixtures applied generally in the cosmetic industry can also be used.
  • the oils act as stabilizing agent in the emulsions and ensure a cosmetically suitable viscosity for the emulsion.
  • Suitable oils are selected from the group consisting of aliphatic hydrocarbons (e.g. liquid paraffine, vaseline, ceresine etc), vegetable oils and fats (e.g. olive oil, almond oil, wheat-germ oil, corn-germ oil, cotton-seed oil, grape-stone oil, jojoba oil, avocado oil, castor oil, palm oil, cocoa butter etc.), animal fats and oils (e.g. cod-liver oil, blubber oil, butyrine, etc.)
  • aliphatic hydrocarbons e.g. liquid paraffine, vaseline, ceresine etc
  • vegetable oils and fats e.g. olive oil, almond oil, wheat-germ oil, corn-germ oil, cotton-seed oil, grape-stone oil, jojoba oil, avocado oil, castor oil, palm oil, cocoa butter etc.
  • animal fats and oils e.g. cod-liver oil, blubber oil, butyrine, etc.
  • compositions according to the invention may contain as other additives e.g. one or more hygroscopic material(s), solubilizing and stabilizing agent, preservative, disinfectant, skin sedating, skin protecting, epithelium regenerating, skin re-fatting, light-protecting and aromatizing materials, vitamins, etc.
  • additives e.g. one or more hygroscopic material(s), solubilizing and stabilizing agent, preservative, disinfectant, skin sedating, skin protecting, epithelium regenerating, skin re-fatting, light-protecting and aromatizing materials, vitamins, etc.
  • hygroscopic materials e.g. glycerol, sorbitol, propylene glycol may be used.
  • solubilizing material e.g. butyl-hydroxy-anisole, butyl-hydroxy-toluene, ethylene-diamine-tetraacetic acid, nor-dihydroguaiaretic acid may be used.
  • a preservative e.g. methyl parabene, p-hydroxy- benzoic acid and esters thereof, chloromethyl-iso- thiazoline, methyl-isothiazoline, phenoxetole, hexetidine, chlorohexidine-gluconate, imidazolinyl-urea can be used. If desired formaldehide and similar other preservatives may also be used.As tonic or disinfectants e.g. menthol, camphor, lactic acid, citric acid, ethanol can be used.
  • panthenol As epithelium regenerating material e.g. allanthoine, panthenol, calcium pantothenate can be used.
  • skin sedating material e.g. chamomile extract, azulenole, bisabolole can be used.
  • cholesterol propane-3-carboxymethyl-betaine, 1- -(alkylamino)-3-(dimethylamino)-propane-3-N-oxide, propane-3-(carboxymethyl)-betaine, alkyl-dimethylamin- oxide, mono- and di-ethanolamide of cocoa acid
  • cholesterol propane-3-carboxymethyl-betaine
  • 1- -(alkylamino)-3-(dimethylamino)-propane-3-N-oxide propane-3-(carboxymethyl)-betaine
  • alkyl-dimethylamin- oxide alkyl-dimethylamin- oxide
  • mono- and di-ethanolamide of cocoa acid e.g.cholesterol, propane-3-carboxymethyl-betaine, 1- -(alkylamino)-3-(dimethylamino)-propane-3-N-oxide
  • propane-3-(carboxymethyl)-betaine propane-3-(carboxymethyl)-be
  • light protecting (sunscreening) material e.g. octyl-dimethyl-PABA, 2-hydroxy-4-methoxy-benzophenone, 2-(ethyl-hexyl)-3-(4-methoxy-phenyl)-2-propenoate, 1-(4- methoxy-phenyl)-3-(4-tert-butyl-phenyl)-propane-1,3- dione, urocainic acid, esculine can be used.
  • vitamin e.g. A, B, B_ , C, E, F, H, P vitamin can be used.
  • aromatizing material e.g. perfumee oil can be used which ensures a pleasant and attractive smell for the composition.
  • composition according to the invention can be formulated into different forms suitable for topical treatment, e.g. cream, ointment, emulsion, solution, tonic, gele, etc. can be prepared.
  • the creams and the ointments according to the invention contain 30-70% by weight of corn extract and 0.05-3% by weight of gamma-linolic acid as active ingredient.
  • the emulsions according to the invention contain 15- -30% by weight of corn extract and 0.05-3% by weight of gamma-linolic acid as active ingredient.
  • the solutions according to the invention contain preferably 30-50% by weight of corn extract and 0.05-3% by weight of gamma-linolic acid as active ingredient.
  • the amount of water and aqueous solvent used in the compositions depends on the consistency of the desired end product.
  • the water used is preferably deionized water and the amount thereof is generally 27-75% by weight calculated for the total amount of the composition.
  • the cream and ointment compositions contain generally at least 20% by weight but max. 60% by weight of water, the water content of the emulsions is preferably 50-70% by weight and that of the solutions preferably 40-70% by weight.
  • Example 1 of HU P No. 195,915
  • Example 6 was prepared according to Example 6 of said patent specification (using ethanol as solvent)
  • the corn extract used in Examples 4, 5 and 7 were prepared according to Example 3 of the same patent specification.
  • corn extracts used in Examples 1-5 were prepared from the crops, hypsophylls, cob, beard and nodulous stalk of the young corn plant, for the preparation of corn extracts used in Example 6 and 7 hypsophylls and crops of corn plant, and hypsophylls, cob and beard respectively, were used.
  • Lanette N mixture of sodium-cetyl-stearyl sulfate and cetyl-stearyl alcohol (Henkel, DE)
  • BRIJ71 ethoxylated stearyl alcohol (JCI, USA)
  • BRIJ721 ethoxylated stearyl alcohol (JCI, USA)
  • Chremophor W07 hydrogenated castor oil (BASF, DE)
  • Genagol AMS detergent and surfactant (Hoechst, DE)
  • Hoe S 3495 ethoxylated fatty acid-polyglycerol ester (Hoechst, DE)
  • composition amounts (g)
  • composition amounts (g) Corn extract 60.00 Gamma linolic acid 0.12 Hostacerin WO 10.00 Light vaseline 5.00 Lanette N 2.00 avocado oil 10.00 Vaseline oil 4.00 Wheat-germ oil 5.00 Example 2 continued
  • composition amounts (g)
  • composition amounts (g)
  • Example 4 Emulsion Composition: amounts (g) Corn extract 15.00 Gamma-linolic acid 0.15 Chremophor WO 7 6.00 Avocado oil 4.00 Corn-germ oil 3.00 Example 4 continued
  • composition amounts (g)
  • composition amounts (g)
  • composition amounts (g)
  • composition amounts (g)
  • composition amounts (g)
  • composition according to the invention were proved by the following clinical tests.
  • Example 1 The composition according to Example 1 was tested on 11 female patients of the age of 21 to 68 years and on 10 male patients of the age of 33 to 73 years. The patients suffered from psoriasis for 12 years on an average. The cream was applied to the injured skin surface 3 times a day and the treatment was continued for 3 weeks. The results obtained are summarized in Table 1. The abbreviations used have the following meaning:
  • Example 1 but containing 45.0 g wheat-germ oil instead of 45 g corn extract was tested on 10 male patients of the age of 32-70 years and on 10 female patients of the age of 20-65 years. The patients suffered from psoriasis for 11 years on an average. The cream was applied to the injured surface 3 times a day and the treatment was continued for 3 weeks. The results obtained are summarized in Table 2.
  • the gamma-linolic acid without corn extract is not suitable for the treatment of psoriasis.
  • composition according to Example 1 containing 0.01 g of wheat-germ oil instead of 0.1 g gamma-linolic acid was tested on 13 male patients of the age of 28 to 60 years and on 7 female patients of the age of 22 to 67 years. The patients suffered from psoriasis for 11 years on an average. The cream was applied to the injured skin surface 3 times a day. The treatment was continued for 3 weeks. The results obtained are summarized in Table 3.
  • Example 6 The composition according to Example 6 was tested on 16 male patients aged from 30 to 60 years and on 13 female patients of the age of 22 to 60 years. The patients suffered from scalp psoriasis, for 10 years on the average. The solution was applied 3 times a day and the treatment was continued for 3 weeks. The results obtained are summarized in Table 4. Table 4

Abstract

Composition pharmaceutique adaptée au traitement topique du psoriasis et comportant à titre d'ingrédient actif un solvant organique aqueux et/ou pharmaceutiquement acceptable, de préférence un extrait éthanolique de jeunes céréales et/ou de l'arête de maïs et/ou de la tige noduleuse de maïs et/ou de la carotte de maïs ainsi que de l'acide linoléique-gamma, mélangés à un ou plusieurs supports solides et/ou liquides et/ou à d'autres additifs.
EP91915231A 1990-08-24 1991-08-23 Composition destinee au traitement topique du psoriasis Ceased EP0497952A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU905312A HU205860B (en) 1990-08-24 1990-08-24 Process for producing pharmaceutical compositiojns for topical treating psoriasis
HU531290 1990-08-24

Publications (1)

Publication Number Publication Date
EP0497952A1 true EP0497952A1 (fr) 1992-08-12

Family

ID=10970056

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91915231A Ceased EP0497952A1 (fr) 1990-08-24 1991-08-23 Composition destinee au traitement topique du psoriasis

Country Status (8)

Country Link
EP (1) EP0497952A1 (fr)
JP (1) JPH05503295A (fr)
CA (1) CA2067770A1 (fr)
CS (1) CS261891A3 (fr)
HU (1) HU205860B (fr)
IL (1) IL99236A0 (fr)
PT (1) PT98757A (fr)
WO (1) WO1992003142A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383499B1 (en) * 1995-10-30 2002-05-07 Curacid America Corporation Topical medicament for the treatment of psoriasis
US6277418B1 (en) * 1998-06-02 2001-08-21 Baylor College Of Medicine Corn extract contraceptive
ITBS20130144A1 (it) * 2013-10-14 2015-04-15 Alejandro Jorge Outon Preparazione per il trattamento della psoriasi
KR101839109B1 (ko) * 2016-09-22 2018-03-15 ㈜프론트바이오 퍼플콘 추출물을 함유하는 피부 질환의 예방 또는 치료용 약제학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239181A1 (de) * 1981-10-23 1983-05-05 L'Oreal, 75008 Paris Wasserfreies, oxydationsstabiles mittel zur behandlung der haut
GB8420771D0 (en) * 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
HU195915B (en) * 1984-09-21 1988-08-29 Tibor Keri Cosmetic preparation of skin regenerating and hydrating effect
DE3512743A1 (de) * 1985-04-09 1986-10-16 Goebel Hans Joachim Mittel zur externen behandlung von psoriasis
DE3836519C2 (de) * 1988-10-26 1994-03-10 Cutan Kosmetik Vertriebs Gmbh Verwendung einer pharmazeutischen Zubereitung auf der Basis von Calendula officinalis zur Behandlung von Psoriasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9203142A1 *

Also Published As

Publication number Publication date
CS261891A3 (en) 1992-03-18
CA2067770A1 (fr) 1992-02-25
IL99236A0 (en) 1992-07-15
PT98757A (pt) 1992-07-31
HU205860B (en) 1992-07-28
WO1992003142A1 (fr) 1992-03-05
HU905312D0 (en) 1991-02-28
JPH05503295A (ja) 1993-06-03

Similar Documents

Publication Publication Date Title
US6197305B1 (en) Anti-fungal compositions with prolonged activity
US5399349A (en) Treatment of acne
US8883225B2 (en) Water-soluble pharmaceutical compositions of hops resins
KR20100095425A (ko) 천심련 추출물
US9415082B1 (en) Compositions and methods for topically treating skin conditions in mammals
EP1871399B1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
MX2008012654A (es) Composiciones novedosas para trastornos del cabello, y procedimiento de preparacion de las mismas.
EA018425B1 (ru) Фармацевтический, дезинфицирующий или консервирующий экстракт пажитника сенного (trigonella foenum-graecum), способ его получения и применение экстракта
JPH07300421A (ja) 抗炎症剤
KR20110082292A (ko) 아토피 및 여드름 피부에 효능을 보이는 황칠나무 추출물
US6419963B1 (en) Composition and method for the treatment of diaper rash using natural products
AU2006239555B2 (en) Hair tonic
US5858372A (en) Herbal medication for the treatment of psoriasis
JP4598900B2 (ja) 口腔歯科分野におけるテルペン類を実質的に含有していないイチョウのフラボノイド抽出物の使用及びかかる抽出物を含有する組成物
US8383166B2 (en) Stable hydrophobic topical herbal formulationn
EP0497952A1 (fr) Composition destinee au traitement topique du psoriasis
JPH04124138A (ja) 皮膚外用剤
EP0348215B1 (fr) Compositions cosmétiques et paramédicinales
JP4197194B2 (ja) 細胞間接着抑制用経口投与剤
JP2004244370A (ja) ニキビ用の皮膚外用剤
EP0717613B1 (fr) Composition stable contenant du jus de germe de ble et procede de production
KR20040056081A (ko) 여드름 예방 및 치료용 화장료 조성물
EP2554179B1 (fr) Composition à base d'un extrait végétal pour le traitement des formes inflammatoires cutanées, en particulier le psoriasis
Edwards et al. Witch Hazel
WO2023218391A1 (fr) Extraits dans des solvants eutectiques de polyphénols d'huile d'olive, compositions, utilisations et procédés de préparation de ceux-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920413

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19950724